PMID- 18607952
OWN - NLM
STAT- MEDLINE
DCOM- 20090311
LR  - 20181201
IS  - 1651-2251 (Electronic)
IS  - 0001-6489 (Linking)
VI  - 129
IP  - 1
DP  - 2009 Jan
TI  - p53, epidermal growth factor receptor and proliferating cell nuclear antigen in 
      laryngeal squamous cell carcinoma are not predictive markers for the effect of 
      adjuvant radiotherapy.
PG  - 101-7
LID - 10.1080/00016480802054185 [doi]
AB  - CONCLUSION: These data indicate that the expression of p53, epidermal growth 
      factor receptor (EGFR) or proliferating cell nuclear antigen (PCNA) is not a 
      reliable predictor of the prognosis or the effect of adjuvant radiotherapy in 
      patients with laryngeal squamous cell carcinoma (LSCC). OBJECTIVE: The aim of 
      this study was to investigate the prognostic significance of p53, EGFR, and PCNA 
      in LSCC and to assess the relationships between the expression of these molecular 
      markers and the effect of adjuvant radiotherapy. PATIENTS AND METHODS: We 
      retrospectively reviewed the expression of these molecular markers in 75 patients 
      with LSCC. RESULTS: None of the expressions of these molecular markers was 
      associated with disease-free survival or overall survival and no significant 
      correlations were found between them and the effect of adjuvant radiotherapy. 
      Also, they were not associated with each other.
FAU - Jiang, Hua
AU  - Jiang H
AD  - Department of Otolaryngology, 2nd Affiliated Hospital, School of Medicine, 
      Zhejiang University, Jie-Fang Road 88, Hangzhou,Zhejiang, China.
FAU - Yang, Bei-Bei
AU  - Yang BB
LA  - eng
PT  - Journal Article
PL  - England
TA  - Acta Otolaryngol
JT  - Acta oto-laryngologica
JID - 0370354
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Proliferating Cell Nuclear Antigen)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/*analysis
MH  - Carcinoma, Squamous Cell/mortality/pathology/*radiotherapy
MH  - Cell Membrane/pathology
MH  - Cell Nucleus/pathology
MH  - Combined Modality Therapy
MH  - Disease-Free Survival
MH  - ErbB Receptors/*analysis
MH  - Female
MH  - Humans
MH  - Laryngeal Neoplasms/mortality/pathology/*radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Proliferating Cell Nuclear Antigen/*analysis
MH  - Radiotherapy, Adjuvant
MH  - Retrospective Studies
MH  - Tumor Suppressor Protein p53/*analysis
EDAT- 2008/07/09 09:00
MHDA- 2009/03/12 09:00
CRDT- 2008/07/09 09:00
PHST- 2008/07/09 09:00 [pubmed]
PHST- 2009/03/12 09:00 [medline]
PHST- 2008/07/09 09:00 [entrez]
AID - 794029532 [pii]
AID - 10.1080/00016480802054185 [doi]
PST - ppublish
SO  - Acta Otolaryngol. 2009 Jan;129(1):101-7. doi: 10.1080/00016480802054185.